ClinicalTrials.gg
Drug

Enlonstobart clinical trials

Also written SG001.

studies test it
19
open now
15
in phase 3
7
first study started
2019

How each study uses enlonstobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the enlonstobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Enlonstobart
4
Enlonstobart injection
2
Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection
2
Recombinant Human Anti-PD-1 Monoclonal Antibody
2

Development codes

SG001
10

Studies by the year they started

19 studies that test it; most in 2026 (6)

Studies that test enlonstobart, by start year
YearStudies
20191
20213
20232
20242
20255
20266

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
14
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 4

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (6) · CSPC Megalith Biopharmaceutical Co.,Ltd. (5) · Shanghai JMT-Bio Inc. (3) · Fudan University (1) · Hebei Medical University Fourth Hospital (1) · Sun Yat-Sen University Cancer Center (1) · Chongqing University Cancer Hospital (1) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1)

Often tested with

Tested in the same studies.

Anti-EGFR Antibody-drug Conjugate CPO301 (4) · Bevacizumab (2) · Anbenitamab (2) · Modified FOLFOX6 Regimen (1) · Suvemcitug (1) · Irinotecan (1) · Fluorouracil (1) · Irinotecan sucrosofate (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test enlonstobart, phase 3 first.

Studies

Open first, then newest update. How each study uses enlonstobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 19

Given beside what is tested · 9 — enlonstobart is usual care or a partner of the new treatment

Codes

What other systems call enlonstobart · ClinicalTrials.gg INT016745

  • UNII (FDA) H533QU433MENLONSTOBARTOne source FDA
  • NCI Thesaurus C182009EnlonstobartOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.